<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00033202</url>
  </required_header>
  <id_info>
    <org_study_id>ST 01-401</org_study_id>
    <nct_id>NCT00033202</nct_id>
  </id_info>
  <brief_title>This is an Early Study to Investigate the Effect of Gimatecan® in Adults With Solid Tumor</brief_title>
  <official_title>Phase I Study of Oral ST1481 Administered Once Weekly Every 3 Out 4 Weeks in Patients With Advanced Solid Malignancies.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sigma-Tau Research, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Rhode Island Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dana-Farber Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sigma-Tau Research, Inc.</source>
  <brief_summary>
    <textblock>
      Gimatecan® is sigma-tau Research's new, potent, oral Topoisomerase I inhibitor. Drugs in this
      class play a crucial role in destroying DNA replication in tumors. We are conducting this
      study to determine the Maximum Tolerated Dose of our compound, when given as a capsule,
      rather than by intravenous injection.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2002</start_date>
  <completion_date type="Actual">February 2005</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Solid Malignancies</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gimatecan® (ST-1481)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Histologically/cytologically proven advanced solid tumors

          -  Life expectancy of at least 3 months with normal hematological, liver and renal
             function

        Exclusion criteria:

          -  Pregnant and lactating patients

          -  Participation in any investigating drug study within 4 weeks preceding treatment start
             or concurrent treatment with any other anti-cancer therapy

          -  Gastrointestinal dysfunction that could alter absorption or motility
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rhode Island Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 9, 2002</study_first_submitted>
  <study_first_submitted_qc>April 9, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 10, 2002</study_first_posted>
  <last_update_submitted>June 2, 2009</last_update_submitted>
  <last_update_submitted_qc>June 2, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 3, 2009</last_update_posted>
  <keyword>Solid Tumor</keyword>
  <keyword>Camptothecin</keyword>
  <keyword>Pharmacokinetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

